Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Zevra Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst O. Livnat now expects that the company will earn $2.51 per share for the year, down from their prior forecast of $2.71. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.92) per share.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the previous year, the business posted ($0.40) earnings per share.
Several other research analysts have also recently issued reports on the company. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $20.00 target price on the stock. William Blair raised Zevra Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Roth Mkm increased their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Finally, Maxim Group lifted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $21.00.
Get Our Latest Stock Analysis on Zevra Therapeutics
Zevra Therapeutics Price Performance
Shares of NASDAQ:ZVRA opened at $8.97 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company's 50 day moving average is $8.09 and its two-hundred day moving average is $6.57. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.27.
Institutional Investors Weigh In On Zevra Therapeutics
A number of institutional investors have recently made changes to their positions in ZVRA. International Assets Investment Management LLC lifted its holdings in shares of Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after purchasing an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics during the first quarter valued at $64,000. Hunter Associates Investment Management LLC acquired a new position in shares of Zevra Therapeutics during the third quarter valued at $92,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter worth about $94,000. Finally, Intech Investment Management LLC bought a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $95,000. 35.03% of the stock is currently owned by institutional investors.
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
